Podcast appearances and mentions of Jefferson Health

Living with polycystic ovarian syndrome or PCOS can take a toll on your emotional and physical health. Common symptoms of this condition are irregular periods, infertility, weight gain and unwanted hair growth – all of which are difficult to cope with.  Listen to the latest episode of The Healthiest You podcast, where we talk about how to manage PCOS with OB-GYN Emily Brophy, MD, with Lehigh Valley Health Network (LVHN), part of Jefferson Health.   What are the symptoms of PCOS? How does PCOS impact ovulation and fertility? What lifestyle changes may help manage PCOS symptoms? Which supplements may provide hormonal support? What diet changes may help women who have PCOS? We answer these questions and more on The Healthiest You podcast this month.Chapters:     · 0:01 - Intro     · 1:00 - What is PCOS?     · 2:05 - Is PCOS genetic?     · 2:46 - Challenges with diagnosing PCOS     · 3:41 - Irregular periods     · 4:38 - Tracking your cycle     · 5:58 - DUTCH test     · 7:21 - PCOS treatment options     · 8:53 - Sharing your diagnosis with your health care team     · 10:08 - Lifestyle changes to help manage PCOS     · 10:58 - Recommended diet changes     · 11:54 - How to reduce the bloating     · 12:37 - PCOS supplements     · 14:57 - Evening primrose oil     · 15:28 - Inositol and PCOS     · 15:47 - Magnesium supplements     · 17:24 - Chasteberry and black cohosh     · 18:21 - Inflammation and PCOS     · 19:11 - Importance of exercise     · 20:30 - Unwanted hair growth     · 22:11 - Spearmint tea     · 22:43 - Ovulation and fertility     · 23:45 - Tracking ovulation     · 25:16 - Mental health and PCOS     · 26:34 - Acupuncture and acupressure     · 28:04 - If you've had your symptoms dismissed      · 29:57 - Advice

Ryan Patterson (Senior Director, Ambulatory Operations at Jefferson Health) and Sherry Onushco (Director at Lehigh Valley Health Network) discuss exciting changes they're making in their networks to streamline checking in, checking out and payment. This episode is brought to you by our good friends at Switch RCM. Please reach out to Nate and the team: Nate@switchrcm.com You will not regret it. Those cats are doing some very interesting things. Don't forget to like and subscribe!

In this episode, Editor-in-Chief Alan Condon breaks down the latest hospital financial trends, including stable margins and rising service volumes. He also discusses the growing tensions in payer-provider negotiations, highlighted by Jefferson Health's contract dispute with Cigna.

In this episode, Scott Becker breaks down seven key healthcare stories, including Cigna and Jefferson Health's contract split, Mercy Health's financial challenges, and a positive upswing in hospital margins.

In this episode, Scott Becker speaks with Dr. Joseph Cacchione, CEO of Jefferson Health and Thomas Jefferson University. Dr. Cacchione discusses the system's growth, the challenges facing healthcare—including reimbursement cuts and financial headwinds—and the importance of integrating care delivery with financing.

Dr. Baligh Yehia, President of Jefferson Health, joins the Becker's Healthcare Podcast to discuss Jefferson Health's growth strategy, workforce development, and the evolving healthcare landscape. He shares insights on the impact of AI, rising healthcare costs, and the significance of hospital mergers, including Jefferson's integration with Lehigh Valley.

Your thyroid is a small, butterfly-shaped gland in your neck that can have a big impact on your health. It's responsible for making hormones that affect your metabolism, heart rate, mood and more.  Listen to the latest episode of The Healthiest You podcast, where we talk about thyroid issues with Andrew Brackbill, MD, endocrinologist with Lehigh Valley Health Network (LVHN), part of Jefferson Health.   Why are women more prone to having a thyroid issue? What is the difference between hyperthyroidism and hypothyroidism? How does Hashimoto's disease affect your health? How might having a thyroid problem impact fertility? Can thyroid conditions impact your mental health? We answer these questions and more on The Healthiest You podcast this month.Chapters:      · 0:01 - Intro     · 0:56 - The main function of your thyroid     · 2:16 - Why women are more likely to have a thyroid problem     · 6:14 - Fatigue and your thyroid      · 12:18 - Symptoms of a thyroid problem     · 13:17 - Temperature intolerances     · 13:58 - Hypothyroidism vs. hyperthyroidism      · 15:45 - Diagnosing thyroid conditions     · 16:57 - How thyroid disorders impact your life     · 19:49 - Hashimoto's disease and hypothyroidism      · 20:49 - Fertility and thyroid conditions     · 23:18 - Menopause and your thyroid      · 25:01 - Diet and your thyroid     · 28:08 - Weight and your thyroid      · 29:51 - Addressing weight issues     · 31:25 - Stress and your thyroid     · 32:45 - Stress management tips     · 33:35 - Mental health and your thyroid      · 36:06 - Wellness strategies      · 38:03 - Treatment options for thyroid conditions     · 44:12 - Getting a thyroid panel     · 45:20 - What is shown in your thyroid panel     · 47:02 - At-home thyroid tests

In this episode, Scott Becker highlights seven major healthcare stories, including Orlando Health's hospital closure, leadership changes at Penn State and Jefferson Health, workforce challenges leading to a UC healthcare worker strike, and growing cybersecurity concerns in health systems.

When it comes to improving heart health, there are simple, science-backed ways to strengthen your heart right from home, according to Dr. Matthew Delfiner, a cardiologist who specializes in advanced heart failure, transplant cardiology, and pulmonary hypertension at Jefferson Health. In this episode, learn about why being sedentary is so bad for your health, how small changes, like standing more and moving throughout the day, can make a big impact and the recommended "dose" of exercise for heart health. Plus, Dr. Delfiner discusses the number one lifestyle change that can have the greatest impact on your heart health. Resources: American Heart Association's Life's Essential 8 How Stress Affects the Heart + Why You Should Never Shovel Snow If You're Over 45 Years Old Cardiologist Discusses Unassuming Warning Signals From Your Heart, Heart Disease and Preventative Medicine

In this episode, Dr. Luis Taveras, Senior Vice President and CIO at Jefferson Health, shares his insights on leading IT integration after the merger with Lehigh Valley Health Network, transitioning to cloud-based systems, and implementing strategic governance models. He highlights the importance of teamwork, leveraging data as a core asset, and navigating challenges like cybersecurity, financial constraints, and the potential of AI in healthcare.

We're thrilled to announce a major milestone for our organization—our brand refresh! Formerly known as the Pennsylvania Action Coalition, we are now the Pennsylvania Nursing Workforce Coalition, a new name that reflects our mission to place Pennsylvania's nursing workforce at the forefront of healthcare. In this episode, we dive into our vision and strategic priorities as we embark on a five-year plan to advocate, support, and advance a nursing workforce that drives a healthier Pennsylvania. Our approach includes three core initiatives: bolstering nursing workforce pathways, reimagining public policy through data, and embracing diversity with equitable solutions. We'll be joined by Daniel Hudson, Vice President and Associate Chief Nurse Executive for Nursing Operations and Administration at Jefferson Health in Philadelphia. Daniel is one of our newest advisory board members, and he brings invaluable expertise in nursing workforce optimization, care delivery, and staff engagement. We'll be discussing the future of nursing, healthcare trends, and how Daniel's extensive experience can help us move closer to our goals.

In this pivotal episode of "The Engineers HVAC Podcast," join Tony Mormino and Frank Campisino, PE, Senior Mechanical Engineer at Barton Associates, Inc., for a deep dive into the critical HVAC challenges faced in healthcare facilities. This discussion, coordinated by Matt Clark of Engineered Building Systems, features John Ardente, Facilities Operations Manager at Jefferson Health. Together, they explore the practical concerns and safety measures surrounding using A2L refrigerants within Jefferson Health's complex environments. Tune in as these seasoned experts tackle flammability risks, adapt to new refrigerant requirements, and offer invaluable insights for HVAC professionals in the healthcare sector. Credit to Chemours for the A2L refrigerant video shown in this presentation.

iHeartMedia is proud to sponsor the Pennsylvania Conference for Women on November 7th—an exciting day featuring Martha Stewart, Sheryl Lee Ralph, Dawn Staley, Robin Arzón, Diana Nyad, and many more inspiring speakers. Plus, your ticket includes free access to the National Conference for Women—a virtual event during Women's History Month that will feature Oprah Winfrey, Gayle King, Gloria Steinem, and others!   As part of our partnership with the conference, we bring you Women Who Inspire. Today, we speak with award-winning leader Dixieanne 'Dixie' James, President of the Central Region at Jefferson Health. Dixie will be speaking on a panel titled "How to Be Engaged, Productive, and Happier at Work," where she explores the importance of happiness in the workplace and how it fuels success. Jefferson Health Links:Website: Jefferson Health - Greater Philadelphia & South Jersey RegionInstagram: @jeffersonhealthFacebook: Jefferson Health on FacebookTikTok: Jefferson Health on LinktreeLinkedIn: Jefferson Health on LinkedInLearn more about the conference at: www.PAConferenceforWomen.orgWe also want to highlight the 38th Annual AIDS Walk Philly on Sunday, October 20th. This 5K walk, hosted by AIDS Fund, raises critical funds to provide emergency financial assistance to people living with HIV in the Philadelphia area. I speak with Robb Reichard, Executive Director of AIDS Fund, and Evelyn Torres, Executive Director of Action Wellness, about the event and its impact. To sign up, visit: www.AIDSwalkphilly.orgLearn more about Action Wellness: actionwellness.orgFinally, we discuss housing insecurity and celebrate Project Home's 35th anniversary. I sit down with Donna Bullock, the new CEO of Project Home, to explore the root causes of housing insecurity and the organization's innovative initiatives to combat homelessness. We also dive into Donna's personal experiences with housing insecurity, which drive her passion for this work. Learn more:Website: www.projecthome.orgInstagram: @projecthomephl

iHeartMedia is proud to sponsor the Pennsylvania Conference for Women on November 7th—an exciting day featuring Martha Stewart, Sheryl Lee Ralph, Dawn Staley, Robin Arzón, Diana Nyad, and many more inspiring speakers. Plus, your ticket includes free access to the National Conference for Women—a virtual event during Women's History Month that will feature Oprah Winfrey, Gayle King, Gloria Steinem, and others!   As part of our partnership with the conference, we bring you Women Who Inspire. Today, we speak with award-winning leader Dixieanne 'Dixie' James, President of the Central Region at Jefferson Health. Dixie will be speaking on a panel titled "How to Be Engaged, Productive, and Happier at Work," where she explores the importance of happiness in the workplace and how it fuels success. Jefferson Health Links:Website: Jefferson Health - Greater Philadelphia & South Jersey RegionInstagram: @jeffersonhealthFacebook: Jefferson Health on FacebookTikTok: Jefferson Health on LinktreeLinkedIn: Jefferson Health on LinkedInLearn more about the conference at: www.PAConferenceforWomen.orgWe also want to highlight the 38th Annual AIDS Walk Philly on Sunday, October 20th. This 5K walk, hosted by AIDS Fund, raises critical funds to provide emergency financial assistance to people living with HIV in the Philadelphia area. I speak with Robb Reichard, Executive Director of AIDS Fund, and Evelyn Torres, Executive Director of Action Wellness, about the event and its impact. To sign up, visit: www.AIDSwalkphilly.orgLearn more about Action Wellness: actionwellness.orgFinally, we discuss housing insecurity and celebrate Project Home's 35th anniversary. I sit down with Donna Bullock, the new CEO of Project Home, to explore the root causes of housing insecurity and the organization's innovative initiatives to combat homelessness. We also dive into Donna's personal experiences with housing insecurity, which drive her passion for this work. Learn more:Website: www.projecthome.orgInstagram: @projecthomephl

iHeartMedia is proud to sponsor the Pennsylvania Conference for Women on November 7th—an exciting day featuring Martha Stewart, Sheryl Lee Ralph, Dawn Staley, Robin Arzón, Diana Nyad, and many more inspiring speakers. Plus, your ticket includes free access to the National Conference for Women—a virtual event during Women's History Month that will feature Oprah Winfrey, Gayle King, Gloria Steinem, and others!   As part of our partnership with the conference, we bring you Women Who Inspire. Today, we speak with award-winning leader Dixieanne 'Dixie' James, President of the Central Region at Jefferson Health. Dixie will be speaking on a panel titled "How to Be Engaged, Productive, and Happier at Work," where she explores the importance of happiness in the workplace and how it fuels success. Jefferson Health Links:Website: Jefferson Health - Greater Philadelphia & South Jersey RegionInstagram: @jeffersonhealthFacebook: Jefferson Health on FacebookTikTok: Jefferson Health on LinktreeLinkedIn: Jefferson Health on LinkedInLearn more about the conference at: www.PAConferenceforWomen.org

As violent crime has trended slightly downward throughout the United States over the last year, a wound to this country's collective psyche that appears reluctant to close is workplace violence in America's hospitals.Reporting the lead story during the next live edition of Monitor Mondays will be special assignment contributor Dennis Jones, senior director of revenue cycle at Jefferson Health.Jones returns to his beat to continue his reporting of this issue. Among those healthcare professionals most at risk for workplace violence are nurses and those who work in emergency rooms. In fact, a 2021 study conducted by the Cleveland Clinic revealed that workplace violence tends to be four times more prevalent in healthcare than in other industries. Jones is expected to have more details on “Violence in America's Hospitals.”Other segments during the weekly Internet broadcast will include these instantly recognizable features:• Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds.• The RAC Report: Healthcare attorney Knicole Emanuel, partner at the law firm of Nelson Mullins, will report the latest news about auditors.• Legislative Update: Cate Brantley, senior government analyst for Zelis, will report on current healthcare legislation.• Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Byron, will join the broadcast with his trademark segment.

In this episode, infectious diseases expert Dr. John Zurlo returns to the podcast to provide essential updates on the latest COVID-19 booster. As we move into the fall season, Dr. Zurlo shares crucial information about whether you should consider getting the updated COVID booster and how to time your flu shot this year for maximum protection. Dr. Zurlo also offers a reminder on what to do if you test positive for COVID, including common symptoms and treatment options. Plus, he provides an update on long COVID, including what symptoms to look out for and how to best advocate for yourself if you think you might have it. Listen and subscribe to the Living Well Podcast by Jefferson Health on your preferred players: Spotify, Apple Podcasts, Podbean.

Dr. Anish Koka, a cardiologist at Jefferson Health, returns to the show for the first time since the inaugural episode in October 2020. With a sharp focus on healthcare policy, he delves into the impact of the Affordable Care Act on his practice, critiques the influence of political biases in academia, and shares his bold ideas for making healthcare insurance accessible and affordable. Dr. Koka also offers insights on prior authorization alternatives, the Inflation Reduction Act, 340B, and much more in this thought-provoking and, at times, contentious discussion. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Dr. Allison Zibelli and Dr. Erika Hamilton discuss the results of the DESTINY-Breast06 trial in HR+, HER2-low and HER2-ultralow metastatic breast cancer and the A-BRAVE trial in early triple-negative breast cancer, the results of which were both presented at the 2024 ASCO Annual Meeting. TRANSCRIPT Dr. Allison Zibelli: Hello, I'm Dr. Allison Zibelli, your guest host of the ASCO Daily News Podcast. I'm an associate professor of medicine and breast medical oncologist at the Sidney Kimmel Cancer Center of Jefferson Health in Philadelphia. My guest today is Dr. Erika Hamilton, a medical oncologist and director of breast cancer research at the Sarah Cannon Research Institute. We'll be discussing the DESTINY-Breast06 trial, which showed a progression-free advantage with the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) compared to chemotherapy in hormone receptor-positive HER2-low or HER2-ultralow metastatic breast cancer. We'll address the implications of this study for the community, including the importance of expanding pathology assessments to include all established subgroups with HER2 expression, and the promise of expanding eligibility for antibody-drug conjugates. We'll also highlight advances in triple-negative breast cancer, focusing on the A-BRAVE trial, the first study reporting data on an immune checkpoint inhibitor avelumab in patients with triple-negative breast cancer with invasive residual disease after neoadjuvant chemotherapy.  Our full disclosures are available in the transcript of this episode.  Erika, it's great to have you on the podcast today. Dr. Erika Hamilton: Thanks so much, Allison. Happy to join. Dr. Allison Zibelli: Antibody-drug conjugates are rapidly changing the treatment landscape in breast cancer. The data from the DESTINY-Breast06 trial suggests that trastuzumab deruxtecan may become a preferred first-line treatment option for most patients with HER2-low or HER2-ultralow metastatic breast cancer after progression on endocrine therapy. First, could you remind our listeners, what's the definition of HER2-ultralow and what were the findings of this trial? Dr. Erika Hamilton: Yeah, those are fantastic questions. Ultralow really has never been talked about before. Ultralow is part of a subset of the IHC zeros. So it's those patients that have HER2-tumor staining that's less than 10% and incomplete but isn't absolutely zero. It's even below that +1 or +2 IHC that we have classified as HER2-low. Now, I think what's important to remember about D-B06, if you recall, D-B04 (DESTINY-Breast04) was our trial looking at HER2-low, is that D-B06 now included HER2-low as well as this HER2-ultralow category that you asked about. And it also moved trastuzumab deruxtecan up into the frontline. If you recall, D-B04 was after 1 line of cytotoxic therapy. So now this is really after exhausting endocrine therapy before patients have received other chemotherapy. And what we saw was an improvement in progression-free survival that was pretty significant: 13.2 months versus 8.1 months, it was a hazard ratio of 0.62. And you can ask yourself, “well, was it mainly those HER2-low patients that kind of drove that benefit? What about the ultralow category?” And when we look at ultralow, it was no different: 13.2 months versus 8.3 months, hazard ratio, again, highly significant. So I think it's really encouraging data and gives us some information about using this drug earlier for our patients with hormone receptor-positive but HER2-negative disease.  Dr. Allison Zibelli: I thought this study was really interesting because it's a patient population that I find very difficult to treat, the hormone receptor-positive metastatic patient that's not responding to endocrine therapy anymore. But it's important to mention that T-DXd resulted in more serious toxicities compared to traditional chemotherapy in this study. So how do you choose which patients to offer this to? Dr. Erika Hamilton: Yeah, those are both great points. So you're right, this is after endocrine therapy. And in fact, about 85% of these patients had received at least 2 prior lines of endocrine therapy. So I have some people kind of asking, “Well, if endocrine therapy really isn't benefiting everyone in the second-line setting post-CDK, should we just move to the ADCs?” And, no, probably we should really make sure that we're exhausting endocrine therapies for those patients that are going to benefit. And once we determine somebody has endocrine-resistant disease, that's when we would think about switching. In terms of the side effects, I think you're right. It's mainly ILD that's probably the more serious side effect that we worry about a little bit with trastuzumab deruxtecan. The good news is, through multiple trials, we've gotten a little bit better at managing this. We've pretty much all but eliminated any fatal cases of ILD, definitely less than 1% now. ILD rates, depending on what study you look for, kind of ranges in that 10% to 15% range. Any grade ILD on D-B06 was 11.3%. So really kind of making sure that we look for ILD at scans, making sure that patients are educated to tell us about any new pulmonary symptoms: cough, exertional dyspnea, shortness of breath at rest, etc. But I think the most common side effects that we really deal with on a daily basis with trastuzumab deruxtecan, luckily, is nausea, which we've gotten better at managing with the 2- or 3-drug antiemetic regimen, and probably a little bit of fatigue as well. Dr. Allison Zibelli: Thank you. So, I think for most people in the community, the sticking point here will be expanding pathology assessments to include all of the subgroups, including the ultralow. Most patients in the community are not testing for HER2-low and HER2-ultralow now. Dr. Erika Hamilton: Historically, we kind of all did HER2 IHC, right? And then as FISH became available, there were a lot of institutions that moved to FISH and maybe didn't have IHC anymore. And now, at least in my institution, we do both. But I think it's a very important point that you made that IHC was really designed to pick out those patients that have HER2-high, the 3 pluses or the FISH amplified cases. It was not to tell the difference between a 1+ or a 2+ or a 0 that's not quite a 0 and a 1+. So I think you're right. I think this is tough. I probably have a little bit more of an interesting take on this than some people will. But data from ASCO, not this year but in 2023, there was actually a pretty eloquent study presented where they looked at serial biopsies in patients, and essentially, if you got up to 4 or 5 biopsies, you were guaranteed to have a HER2-low result. Now, this didn't even include ultralow, which is even easier. If we know we include ultralow, we're really talking about probably 85% to 90% of our patients now that have some HER2 expression. But if we biopsy enough, we're guaranteed to get a HER2 low.  And so I think the question really is, if we know IHC wasn't really designed to pick out these ultralows, and we know kind of greater than 90% of patients are going to have some expression, did we kind of develop this drug a little bit backwards? Because we thought we understood HER2, and the reality is this drug is a little bit more like a sacituzumab govitecan, where we don't test for the TROP2. Should we really be kind of serial biopsying these patients or should maybe most patients have access to at least trying this drug?  Dr. Allison Zibelli: So I don't think that most of my patients will really be happy to sign up for serial biopsies. Dr. Erika Hamilton: Agreed. Dr. Allison Zibelli: Do we have any emerging technologies for detecting low levels of HER2? You talked about how the IHC test isn't really designed to detect low levels of HER2. Do you think newer detection techniques such as immunofluorescence will make a difference, or will we have liquid biopsy testing for this? Dr. Erika Hamilton: Yeah, I think liquid biopsy may be a little bit hard, just because some of those circulating tumor cells are more of a mesenchymal-type phenotype and don't necessarily express all of the same receptors. Normally, if they're cytokeratin-positive, they do, but certainly there is a lot out there looking at more sensitive measures. You mentioned immunofluorescence, there are some even more quantitative measures looking at lower levels of HER2. I definitely think there will be. I guess, ultimately, with even the IHC zeros that are the less than 10% incomplete staining, having a PFS that was absolutely no different than the HER2 low, I guess the question is, how low can we really go? We know that even the IHC zeros doesn't mean that there's no HER2 expression on the cell surface. It just means that maybe there's a couple of thousand as opposed to 10,000 or 100,000 copies of HER2. And so it really appears that perhaps this drug really is wedded to having a lot of HER2 expression. So ultimately, I wonder how much we're going to have to use those tests, especially with what we know about tumor heterogeneity. We know that if we biopsy 1 lesion in the liver, biopsy a lymph node, or even another lesion in the liver, that the HER2 results can have some heterogeneity. And so ultimately, my guess is that most people have some HER2 expression on their breast cancer cells. Dr. Allison Zibelli: So maybe we're going to be using this for everybody in the future. Dr. Erika Hamilton: It certainly seems like we keep peeling back the onion and including more and more patients into the category that are eligible to receive this. I agree. Dr. Allison Zibelli: Let's move on to triple-negative breast cancer, namely the A-BRAVE trial. This was an interesting trial for patients that did not get neoadjuvant immunotherapy and testing 2 groups. The first group was those with residual disease after neoadjuvant conventional chemotherapy. The second group was people with high-risk disease identified upfront that had upfront surgery. The study found that adjuvant avelumab did not improve disease-free survival versus observation, which was the study's primary endpoint. But interestingly, there was a significant improvement in 3-year overall survival and distant disease-free survival. Can you give us your thoughts on that? Dr. Erika Hamilton: Yeah, I think this study was really interesting. Right now, the standard for our patients with larger or node-positive triple-negative cancers is KEYNOTE-522. It's a pretty tough regimen. It's kind of 2 sequential uses of 2 chemotherapies, so 4 chemotherapy agents total with pembrolizumab. But you're right, this study looked at those that had residual disease after neoadjuvant that didn't include immunotherapy, or those patients that didn't get neoadjuvant therapy, went to surgery, and then were receiving chemotherapy on the back end. I'm going to give you the numbers, because you're right. The 3-year disease-free survival rates were not statistically significant. It was 68.3% among those that had avelumab, 63.2% with those that had observation only. So the difference was 5.1% in favor of avelumab, but it wasn't statistically significant. A p value of 0.1, essentially. But when we looked at the 3-year overall survival rates, we saw the same pattern, those patients with the avelumab doing better, but it was 84.8% overall survival and not, unfortunately, dying, versus 76.3%. So the magnitude of benefit there was 8.5%, so about 3% higher than we saw for disease-free survival, and this was statistically significant.  So is this going to change practice for most patients? I probably don't think so. I think for our patients that have larger tumors that's recognized upfront or have node positivity, we're probably going to want to use neoadjuvant chemo. Being able to get a PCR is very prognostic for our patients and enables us to offer things on the back end, such as PARP inhibitors or further chemotherapy of a different type of chemotherapy. But for our patients that go to surgery and maybe the extent of their disease just isn't recognized initially, this could be an option. Dr. Allison Zibelli: I agree. I think this will be a really useful regimen for patients where we get the surprise lymph node that we weren't expecting, or somebody who comes to us, maybe without seeing the medical oncologist, who got upfront surgery. So I thought this was really interesting. What kind of translational studies do you think we're going to do to try and understand which patients would benefit from avelumab? Dr. Erika Hamilton: Yeah, I think that's a great question, and honestly, it's a question that we haven't really answered in the neoadjuvant setting either. Immunotherapy in breast cancer is just a little bit different than it is in some other diseases. We have a benefit for those patients that are PD-L1 positive in the first line. We really haven't seen benefit for metastatic outside of first line. And then in neoadjuvant, it was among all comers. We don't have to test for PD-L1. And now we have this avelumab data from A-BRAVE. I think the question is, is there's probably a subset of patients that are really getting benefit and a subset that aren't. And I don't know that PD-L1 testing is the right test. We know a lot of people are looking at TILs, so kind of lymphocytes that are infiltrating the tumor, a variety of other kind of immunologic markers. But my guess is that eventually we're going to get smart enough to tease out who actually needs the immunotherapy versus who isn't going to benefit. But we're not quite there yet. Dr. Allison Zibelli: Thank you, Erika, for sharing your valuable insights with us on the ASCO Daily News Podcast today. Dr. Erika Hamilton: Thanks so much for having me.  Dr. Allison Zibelli: And thank you to our listeners for joining us. You'll find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you like this podcast and you value our insights, please take a moment to rate, review, and subscribe wherever you get your podcasts. It really helps other people to find us. So thank you very much for listening today.   Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    Find out more about today's speakers:  Dr. Allison Zibelli Dr. Erika Hamilton @ErikaHamilton9   Follow ASCO on social media:  @ASCO on Twitter    ASCO on Facebook    ASCO on LinkedIn      Disclosures: Dr. Allison Zibelli:  None Disclosed   Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

According to the National Institute on Aging, more than one million women and people assigned female at birth (AFAB) in the United States experience menopause each year. Yet, understanding its symptoms and treatment pathways remains a mystery for many. “For every woman, it's an individual journey,” explains Dr. Robyn Faye, a gynecologist and a certified menopause practitioner through the Menopause Society. “I think some women think that their journey is going to be really easy and they're shocked at how difficult it can be. For some women, it's only going to be some hot flashes and some night sweats. For some women, it's just going to be the period is going to change and it's going to stop. And for some women, it's going to be over a hundred different symptoms.” Dr. Faye joins the podcast to provide a comprehensive overview of menopause. She discusses the different stages, symptoms, and treatment options, emphasizing the unique experiences of each woman. Dr. Faye also highlights the importance of open communication and finding support during this transitional period.   Resources: Jefferson Health Wellness Webinar: Let's Talk About Menopause Women's Health Initiative Study: The Women's Health Initiative Hormone Therapy Trials: Update and Overview of Health Outcomes During the Intervention and Post-Stopping Phases Additional Reading: The Truth About Menopause: Debunking 6 Common Misconceptions Listen and subscribe to the Living Well Podcast by Jefferson Health on your preferred players: Spotify, Apple Podcasts, Podbean.

If you're enjoying this interview click this link to join Dr. Ramsey's weekly newsletter and to download free resources: https://drewramseymd.com/free-resources/ The medical profession is undergoing a transformative shift as it intersects with the rapid advancements in artificial intelligence, digital technologies, and social media. In this episode, we explore how these emerging domains are shaping the future of healthcare and impacting the mental health and well-being of medical practitioners. We speak to Dr. Austin Chiang, Chief Medical Officer for the Endoscopy business of Medtronic, about his experience working in the medical field. He shares openly about the importance of mental health, creativity, and sharing knowledge on social media.  Being a Gastroenterologist, he also provides practical advice for optimizing your gut health and supercharging your nutrition.  ==== 0:00 Intro 2:24 Shedding Light on Gut Health 4:18 Being a Endoscopist 6:50 When to See a Gastroenterologist  11:16 Fundamental Ways to Help the Gut 13:35 Fiber Foods & Supplements 18:52 AI & Gastroenterology 27:53 Taking Care of Mental Health on the Road 31:26 Working on Innovation with Medtronic 33:56 Creativity in Medicine 36:13 How Social Media is Changing Medicine 40:09 Mental Health Tips for Making it Through Med School 44:45 Healthy Boundaries with Social Media 50:06 Sharing Vulnerably  53:33 Giving People the Tools to Share on Social Media 56:50 Conclusion ==== Dr. Chiang is the first Chief Medical Officer for the Endoscopy business of Medtronic, the global leader in health technology. He is also currently an Assistant Professor of Medicine at an academic teaching hospital in Philadelphia, PA, and serves as the Director of the Endoscopic Weight Loss Program. He completed his undergraduate studies at Duke University before earning his MD at Columbia University. He stayed for Internal Medicine residency at New York Presbyterian Hospital and completed his GI and bariatric endoscopy fellowships at Brigham and Women's Hospital. He obtained his MPH from the Harvard TH Chan School of Public Health before completing an advanced endoscopy fellowship at Jefferson.  Passionate about empowering patients with accurate medical information online, he is one of the most influential voices in the field of gastroenterology across multiple social media platforms including Instagram, X/Twitter, TikTok, and YouTube with over 700,000 followers and over 180 million views. Dr. Chiang has conducted extensive research in social media and is champion of physician presence on social media and was formerly the Chief Medical Social Media Officer of Jefferson Health and Founding President of the Association for Healthcare Social Media (AHSM, @ahsm_org), the first 501(c)(3) professional society for health professional social media use. He has worked closely with all major national GI societies on social media efforts and was 2018's Healio Gastroenterology Disruptive Innovator of the Year, The Philadelphia Inquirer's 2019 Influencers of Healthcare Rookie of the Year, and among 2019 Medscape Top 20 Social Media Physicians, and a 2021 GLAAD Media Award Nominee. He spoke at South by Southwest (SXSW) 2021, and his role in social media has been featured by The New York Times, CNBC, and BBC News. He sits on the inaugural YouTube Health Advisory Board and in 2022, joined the White House Healthcare Leaders in Social Media Roundtable.  In April 2024 he will be releasing Gut: An Owner's Guide (DK/Penguin Random House) an illustrated, colorful book to help educate the general public about their gut health, gastroenterological procedures, and innovation. Website: https://www.austinchiang.com/ Book: https://www.austinchiang.com/gut-book ==== Connect with Dr. Drew Ramsey: Instagram: https://www.instagram.com/drewramseymd/ Website: https://drewramseymd.com

Our miniseries on how stress affects the body concludes with a focus on gut health. In this episode, gastroenterologist Dr. Cuckoo Choudhary shares the ways stress shapes our digestive system and how it can affect gastrointestinal motility, sensitivity, gut microbiome and more.  Dr. Choudhary also discusses symptoms of stress-related GI issues and shares how some chronic GI disorders can be triggered or aggravated by stress in genetically predisposed individuals. We also talk about ways to maintain a healthy gut, including diet tips and stress techniques.     Resources:   Miniseries | How Stress Affects the Body: Heart Episode (1/3)  Miniseries | How Stress Affects the Body: Nervous System Episode (2/3)  Making Healthy Food Choices: How to Read the Nutrition Facts Label  How to Recognize the Signs of and Prevent Burnout  Podcast: Dietitian Reviews TikTok Nutrition Trends, Diets and More  Podcast: Gastroenterologist Takes on Questions About Gut Health, Celiac Disease, Colonoscopies and More  Listen and subscribe to the Living Well Podcast by Jefferson Health on your preferred players: Spotify, Apple Podcasts, Podbean. 

Tune in to the latest episode of the Becker's Healthcare Podcast, recorded live at our 14th Annual Meeting, where we delve into insightful discussions with industry experts. Join Dr. Stacey-Ann Okoth, SVP, System Associate Chief Nurse Executive at Jefferson Health, as they share invaluable insights on leadership, growth strategies, and navigating workforce challenges in healthcare. Gain actionable advice and best practices to elevate your organization's performance in today's dynamic landscape.

Dr. Allison Zibelli and Dr. Megan Kruse discuss the potential benefit of endocrine therapy in ER-low breast cancer; the efficacy and tolerability of triplet therapy in PIK3CA-mutated, HER2-negative locally advanced or metastatic breast cancer; and more key research that will be featured at the 2024 ASCO Annual Meeting.  TRANSCRIPT Dr. Allison Zibelli: Hello, I'm Dr. Allison Zibelli, your guest host of the ASCO Daily News Podcast today. I am an associate professor of medicine and a breast medical oncologist at the Sidney Kimmel Cancer Center of Jefferson Health in Philadelphia. My guest today is Dr. Megan Kruse, a breast medical oncologist and director of breast cancer research at the Cleveland Clinic Taussig Cancer Institute. We'll be discussing key abstracts in breast cancer that will be featured at the 2024 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode, and disclosures related to all episodes of the podcast are available at asco.org/DNpod.  Megan, it's great to have you back on the podcast. Dr. Megan Kruse: Thanks, Alison. Happy to be here. Dr. Allison Zibelli: So, let's begin with Abstract 505. This was another analysis of the SWOG S1007 (RxPONDER) trial, which was the trial that was looking at premenopausal women with intermediate risk oncotype scores. And do they benefit from chemotherapy? If you analyze the whole group, they do benefit from chemotherapy, but what this study questions is whether we can pull out the subset of these patients that actually benefit from chemotherapy? And what they tried doing was measuring various endocrine reproductive hormones and found that anti-mullerian hormone over 10 was the only one that predicted for chemotherapy benefit. What are your key takeaways from this study? Will it help us figure out who is truly postmenopausal biochemically? Dr. Megan Kruse: I think this is really promising. This is one of the toughest situations in clinic, honestly, when you have a premenopausal woman who has an intermediate oncotype risk. We know that chemotherapy is not going to make a huge difference potentially in their breast cancer outcomes, but it may add to some small differential benefit. I think that many of our patients are really afraid about leaving any impactful therapy on the table. And so, it'd be nice to have another marker to help sort out who in this group will really benefit. And the AMH levels, I think, are something that are very accessible for most practices, easily orderable. And it seems like this cutoff of 10 is a very well-known cut point in the AMH interpretation, and a pretty clear-cut point. So, I think it gives a little bit more objective view of who may actually benefit or not.  When you look at the results shown in this abstract, for the women in the recurrence score less than 25 receiving chemotherapy followed by endocrine therapy, they had a benefit in five-year invasive disease-free survival of 7.8%. When you look at those oncotype reports and they suggest how much benefit you might get, that's right around the same number you see. So, I think that's supporting that this is the subgroup that's benefiting.  When you look at those patients with AMH less than 10, they actually had a negative 1.7% difference in overall survival. So, you wonder, are we harming these patients by giving them chemotherapy? I think that's too far of a stretch to say. I wouldn't be worried about harm. But hopefully, we can stop giving chemotherapy to patients who truly are not going to benefit if we have an additional biomarker of response. That's what the promise is for this.  So again, another potentially actionable abstract that we can put into practice pretty quickly. It's going to be hard to know how to use this, also in the context of the upcoming OFSET study or BR009, which is of course the study in the same group of premenopausal patients with node-negative or 1-3 lymph nodes involved, and intermediate oncotype scores, randomizing them to endocrine therapy with ovarian suppression versus chemoendocrine therapy. It would be kind of nice to see the AMH levels incorporated into that model to see if the same trend holds true. But I think we go back to the TAILORx and RxPONDER studies many times as good quality data, and the trend here is really striking.  Dr. Allison Zibelli: I really like this study because one of the things I often struggle with in the clinic as a practicing breast oncologist is who's really in menopause. And we end up having these fights with the gynecologists where sometimes our opinions differ. And it would be really nice to have something this clear cut to say, “You're in biochemical menopause or you're not.” So, I look forward to seeing this used in a lot of different ways in the future.  Dr. Megan Kruse: Yeah, I agree. And I think it's based on the other markers we have with estrogen levels, with FSH levels. If you're checking those sequentially in patients, we know they go up and down, and it's really hard to tell what we are capturing at this single point in time. And maybe that's what we're seeing in this analysis is that the AMH is a little bit more stable and reliable marker. So, I really love that. And I don't know about you, but in clinical practice it can be really hard. A lot of our patients have had uterine ablations or hysterectomies but have intact ovaries. And so, figuring out ovarian function status is actually much, much harder than it may seem superficially.  Dr. Allison Zibelli: Okay, so let's focus on Abstract 513. I thought this was really interesting. It's a group of patients that we don't have much data for, and that's women that are ER-low, with an ER of 1% to 10% in early-stage breast cancer. Right now, national guidelines are sort of on the fence about whether these women benefit from endocrine therapy. So that's what this study tried to focus on. How will this study change how we approach this group of patients? Dr. Megan Kruse: This study really gave me pause and made me rethink what I'm doing on a day-to-day basis, because here, what the authors found in a very large NCDB analysis was that for women with ER-low status, so ER 1% to 10% positive, they actually did have benefit receiving endocrine therapy, it seems. What they found, after you adjust for many other confounding factors like age, comorbidity, and PR status, is that patients with ER-low breast cancer when they did not receive endocrine therapy actually had worse overall survival outcomes with a hazard ratio of around 1.2 to 1.3.  This is a group where I have typically not pushed endocrine therapy very strongly. I think the patients, especially now, are receiving such intense therapy with chemoimmunotherapy in the preoperative setting, by the time they reach their adjuvant phase with immunotherapy, maybe with capecitabine, maybe with a PARP inhibitor, endocrine therapy seems, “Oh, why bother after we've done all of this?” And we know that the toxicities of endocrine therapy are real and can be very problematic. And so, I have often felt like it's the least important part of therapy and questioned whether we should even bother. But I think this analysis really challenges that and makes us think twice. And I think it speaks to a theme that we're seeing more and more about the heterogeneity of these breast cancer subtypes. And again, talking about clear-cut points in analysis, nothing is truly black and white. So maybe that little bit of expression does mean something.   It does kind of stand in contrast to what we see in studies of ER-low behaving a bit more triple-negative like, but maybe they're their own category, and maybe it gives us a place to look for other therapy synergy in the future. But it certainly will make me stop and think again when I see a ER 4% patient. Should I talk to them about endocrine therapy?  Dr. Allison Zibelli: Yeah, I totally agree with everything you said there. And we know that this is a biologically different group of patients than the ER strongly positive group, but maybe not as different as we once thought. Dr. Megan Kruse: Yeah. And I think there's still a lot of unknowns here about what if they're ER truly negative and PR a little bit positive. So, these clinical situations don't come up that frequently, but when they do, they're humbling, because I think we really, as much data as we have in breast cancer, it's pretty limited for these types of patients.  Dr. Allison Zibelli: So, let's move on to Abstract 1003, which was a new combination in the INAVO120 trial. It was palbociclib plus fulvestrant with either inavolisib or placebo in patients with PIK3CA-mutated hormone receptor-positive, HER2-negative, locally advanced metastatic breast cancer in the second line, who relapsed within 12 months of adjuvant endocrine therapy completion. This is a big group of patients for us. Can you tell us about the study? And does this triple therapy, in your mind, represent a new standard of care? Dr. Megan Kruse: Yeah, this study was initially presented at our 2023 San Antonio Breast Cancer Symposium, and there I felt like it was a little bit of a surprise. There's been so much talk about PI3K-AKT-PTEN pathway impactful drugs and targetable mutations. We've heard a lot about alpelisib and capivasertib, and how these drugs are fitting into our practice. Then all of a sudden, we have this data with inavolisib that I wasn't really expecting to see. And perhaps I think one of the reasons that this study came about so suddenly, seemingly, and so quickly is because it looks at a really high-risk patient population. And so, these are those patients that are having relapses of their breast cancer within their initial, while on adjuvant AI therapy or within 12 months of stopping. And so, having a marker of this patient group that is developing, I think, early endocrine resistance and it's another space where it's kind of hard to identify who these patients are upfront. And so their response to therapy tends to be one of the best markers of risk moving forward.   So, when this trial was originally presented, what was quite striking is that the progression-free survival was more than doubled for the triplet combination compared to the control arm. And those numbers were PFS of 15 months versus 7.3 months for the triplet versus the control. The response rate was also significantly improved, with the triplet going above 50%, versus a response rate in the control of about 25%. So, the results were really striking. But they clearly come with some caveats, which are that this is a very defined patient population of risk. Of course, they have to have the biomarker of a PIK3CA mutation, and in the control arm here, there was no PIK3-targeted medication. And so you wonder, are we just getting better results by including that more specific targeted therapy earlier on? It's hard to know, but I think that could certainly be a big part of this.  And the other caveat, when I'm looking at the data, is how might we think about this in our real population? Because as we know, drugs that impact this pathway tend to have a lot of toxicity concerns, primarily hyperglycemia, diarrhea, and rash. And with this particular agent, there was also notable stomatitis, which is something we've seen with everolimus, of course, in this pathway, but not maybe as much with alpelisib and capivasertib. When you're thinking about all of those toxicities, keep in mind that this trial population included patients with a pretty tight fasting blood sugar requirement, A1c of less than 8, and not requiring insulin. So all of that being said, I think this combination seems really intriguing for efficacy. This is a patient population I'm worried about, because we know that these patients are likely not going to get the same upfront benefit of CDK4/6 inhibitor-based therapy, like maybe we see for a patient with long disease-free survival or de novo metastatic breast cancer. But I think it's going to have some meaningful issues in clinic regarding tolerability. And then, of course, the regimen is more complex. We're talking about two different oral agents and an intramuscular injection, which could be hard for some patients, and it's going to have some decent financial toxicity associated with it.  So, I think it's really, really exciting and has the potential to make an impact in first-line therapy. But I don't envision it being the standard of care first-line therapy for everyone, particularly in light of some of the other data we have in the first line questioning, like from the SONIA trial, how important is CDK for everyone? Again, this is I think where we're starting to get subsets within subsets of this first-line patient population of who needs escalation of therapy and who may benefit from more de-intensified therapy. Dr. Allison Zibelli: I agree, these agents have significant toxicity, and especially financial toxicity is something that we at the academic setting frequently forget about because a lot of our patients are on trials. So, it will be interesting to figure out how we're going to use these agents in real life.  So, for our final abstract, I wanted to discuss Abstract 10508, which was a prevention trial. I think pretty much everybody's patients are going to be asking them about this because it's about GLP-1 inhibitors. We know that bariatric surgery does prevent obesity-associated cancers. This study explored whether the GLP-1 agonists could offer a similar result to bariatric surgery in patients with BMIs over 35. What do you think about this study?  Dr. Megan Kruse: I thought this was such an interesting and timely study and question. These drugs are out there – Ozempic, Mounjaros, and Wegovy – and our patients ask about them. And I think there has been a lot of interest for years now about the impact of lifestyle factors on cancer incidence, particularly in breast cancer, where we know that obesity does seem to be related to cancer incidence. And with all of our concerns about hormonal exposure and extra weight, extra adipose tissue being a source of potential extra estrogen, this is a really key topic.   Talking about financial toxicity, again, I think that is honestly probably the bigger hurdle because this study does reinforce that patients who are receiving GLP-1 receptor antagonists and those who have had bariatric surgery do benefit in terms of cancer-related survival and all-cause related survival. So, I think the impact on metabolic factors is making a difference in cancer incidence and outcomes. But access and equity will be the big issue here, right? Dr. Allison Zibelli: Yes. Dr. Megan Kruse: Can we get patients on these drugs? I certainly have had patients with a history of breast cancer who have been on these medications, and they have done great with them in terms of weight loss. We know that our therapies, many times, do have the side effect of weight gain. So, I wonder if there is a part of weight management that maybe we haven't talked about so much as oncologists that we need to talk about moving forward and would be very welcome by our patients. But it'll have its own caveats, of course. Not only the financial issue but there's the durability issue. And I think when you look at the degree of impact of these medications versus bariatric surgery, you do see a greater impact from bariatric surgery, in not only the degree of weight loss but also the sustainability of that weight loss. So, I think for the right patient at the right time, bariatric surgery may still be the better option, but that's not going to be an option for a lot of patients. It is a huge shift in lifestyle and medications and many ways might be easier, so more to come.   I also wonder about looking at this data through the lens of different cancer types. What will we find out? Is the trend for colon cancer going to be different from the trend for breast cancer? Will the trend within breast cancer be different for breast cancer subtypes? I would very much welcome more data in this space, and it is nice to see a first step forward. Dr. Allison Zibelli: I thought the most interesting thing about this study was that while bariatric surgery patients lost more weight, GLP-1 patients had a higher decrease in obesity-related cancer risk. So, it shows to me that there is something beyond just weight. It is something in metabolism that is driving these cancers.  Dr. Megan Kruse: Yes, and I think that that goes back to some things we have thought about for a long time with insulin levels and insulin-like growth factor, and all of these things that I think when our patients look at more metabolic approaches to cancer control, this is probably what we are trying to get at. We have just never had great ways to measure it or influence it, and perhaps now we finally do. I would love to see some partnering work here in the future with oncologists and endocrinologists and digging into these patients who have great responses to see what we are actually seeing at the hormone level. Dr. Allison Zibelli: Well, thank you so much, Megan, for your great insights today on the ASCO Daily News Podcast. We really appreciate you coming to talk with us again. Dr. Megan Kruse: Thank you. It has been a great conversation. Thank you for opening my eyes to these abstracts, and I am happy to see what else ASCO brings. Dr. Allison Zibelli: And thank you to our listeners for joining us today. You will find links to all the abstracts we discussed today in the transcript of this episode. Finally, if you value the insights you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. It really helps other people find us. Thank you for listening.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. The guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow today's speakers: Dr. Allison Zibelli Dr. Megan Kruse @MeganKruseMD   Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn   Disclosures: Dr. Allison Zibelli: None Disclosed   Dr. Megan Kruse: Consulting or Advisory Role: Novartis Oncology, Puma Biotechnology, Immunomedics, Eisai, Seattle Genetics, Lilly

Are you struggling to wrangle your organization's indirect spend and purchased services? In this week's eye-opening episode, we sit down with Rick Gresko, Vice President of Procurement at Jefferson Health, to uncover insider strategies for tackling these procurement challenges head-on. From navigating the blurry lines between indirect spend and purchased services to leveraging data for strategic decision-making, Rick shares his expertise on bringing value to traditionally commodity-based purchases. Tune in to discover how you can build credibility with internal stakeholders, manage supplier relationships with finesse, and negotiate your next contract like a pro. Whether you're up on the latest procurement management techniques or just diving into these complex waters, this episode is packed with practical insights and game-changing strategies you won't want to miss. Grab your headphones and press play today! Once you complete the interview, jump on over to the link below to take a short quiz and download your CEC certificate for .5 CECs!  -- https://www.flexiquiz.com/SC/N/ps10-4 #PowerSupply #Podcast #AHRMM #HealthcareSupplyChain #IndirectSpend #PurchasedServices #Procurement

“I think a virtual nurse can have the same sort of presence that a bedside nurse does. I like to think of a virtual nurse as pulling up a virtual chair next to that patient and spending time to ask questions and engage with them,” Laura Gartner, DNP, MS, RN, NEA-BC, associate chief nursing informatics officer for inpatient shared services and north region at Jefferson Health in the Philadelphia, PA, area told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about virtual nursing care. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by May 17, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to virtual nursing. Episode Notes  Complete this evaluation for free NCPD.  Oncology Nursing Podcast episodes: Episode 282: Telehealth-Based Oncology Palliative Care Episode 136: Nurse Innovators Use Telehealth to Improve Adult and Pediatric Symptom Reporting Episode 109: Is Telehealth the Future of Cancer Care? ONS Voice articles: How's Your Video Telehealth ‘Webside Manner'? Innovative Solutions to Maximize Oncology Nurse Staffing During a Nursing Shortage Personalized Patient Education: Ensure Effective, Inclusive, and Equitable Patient Education With These Five Strategies Telehealth: The Future Is Now for Patient-Centered Care ONS book: Telephone Triage for Oncology Nurses (third edition) Clinical Journal of Oncology Nursing articles: Nursing Telemedicine Educational Encounters: Improved Patient Satisfaction in Radiation Therapy Clinics Oncology Nurse Navigation: Expansion of the Navigator Role Through Telehealth Telehealth Use in Rural North Carolina Counties: Perceptions Among Patients With Acute Myeloid Leukemia Telemedicine Versus Clinic Visit: A Pilot Study of Patient Satisfaction and Recall of Diet and Exercise Recommendations From Survivorship Care Plans Oncology Nursing Forum articles: A Telemedicine-Delivered Nursing Intervention for Cancer-Related Distress in Rural Survivors Breast Cancer Survivors' Satisfaction and Information Recall of Telehealth Survivorship Care Plan Appointments During the COVID-19 Pandemic Rural Cancer Survivors' Perceptions of a Nurse-Led Telehealth Intervention to Manage Cancer-Related Distress Telenursing Interventions for Patients With Cancer Receiving Chemotherapy: A Scoping Review ONS Clinical Practice Resource: Racial Disparities in Cancer Care: Telehealth and Clinical Trial Options Jefferson Health press release: Jefferson Health Launches Virtual Nurse Program To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “I think that the virtual nurse plays a really important role in nurse staffing shortages. With this shortage, we need to get creative and think outside the box so that we can facilitate nurse wellness, work-life balance, and satisfaction and make our hospitals the place that nurses want to work. I firmly believe that nothing can replace the physical touch, but there are so many things a nurse does every day that can be done by somebody remotely that can reduce the workload of that bedside nurse.” TS 3:28 “About eight nurses between these two floors have volunteered to take on this role as a virtual nurse, and so they will come right from that floor. But there's a lot of conversation about whether you should use staff from the floor, if you should use other people, things along those lines. But right now, we really hope and think that the nurses we've identified for this phase have a relationship with these units. They know how the units work, and that might help get everybody working together.” TS 6:37 “We found that it was really important to have a virtual knock for the patient so that you're not just popping into a room and taking a patient off guard. Privacy features for the patient—so if there's a camera pointing at the patient all the time, that gives a patient a little unease. ‘Is somebody watching me?' And when we weren't really watching them all the time; it was intermittent care, so having a camera turn away from the patient when it's off or have a clear indicator that it's not on.” TS 11:57 “In terms of lessons learned with the virtual staff…I don't think that you can just take any nurse off the floor and put them behind a camera. There is a bit of a ‘webside manner,' if you will. People need to be comfortable doing things remotely where they can't touch the patient, or having a conversation with somebody through a camera might not be a skill that everybody has or is comfortable doing.” TS 13:39 “I don't think a virtual nurse can replace that physical touch. What I see a virtual nurse is, is another member of the care team whose care complements the care the bedside nurse is providing. I don't think that we should be looking to remove resources from the bedside with this nursing shortage but rather evaluate what our nurses are doing, identify if there's tasks that someone else can do for them so that they can focus on the patient. And there are plenty of things that a virtual nurse could do so that the bedside nurse can spend more time doing quality work with that patient.” TS 21:40

Jefferson Health and Lehigh Valley Health Network sign an agreement to merge. Preliminary data shows a drop in overdose deaths in 2023. Marking the first decline in years. And Novo Nordisk will test whether its weight-loss drugs can help people with alcohol-related liver disease. That's coming up on today's episode of Gist Healthcare Daily. Hosted on Acast. See acast.com/privacy for more information.

Welcome to part two of our three-part series examining the effects of stress on the body. In this episode, neurologist and sleep specialist Dr. Zhikui Wei discusses how stress specifically impacts how the nervous system functions, including the brain.      Dr. Wei explains the distinction between acute and chronic stress responses, delving into how both types of stress affect the brain's neurotransmitters, tissue remodeling in the brain, and overall mental health. He also offers insights on recognizing symptoms of stress and shares tips for managing stress, including the mindfulness practice he uses to reduce stress in his life.  Resources:  Top Sleep Mistakes and How to Get Better Sleep  Listen and subscribe to the Living Well Podcast by Jefferson Health on your preferred players: Spotify, Apple Podcasts, Podbean. 

Recorded live at the 11th Annual Becker's Healthcare CEO + CFO Roundtable, this episode features Joseph Cacchione, Jefferson Health and Thomas Jefferson University. Here, he discusses payer -provider relations, the consumer experience, the importance of supporting the needs of the most vulnerable members of your community, and more.This episode is brought to you by R1 RCM, a leading provider of technology-driven solutions that transform the financial performance of hospitals, health systems, and medical groups. R1 delivers proven, scalable operating models that power sustainable improvements to net patient revenue, while reducing operating costs. To learn how you can build a future-ready revenue cycle today, visit us at www.r1rcm.com/beckers

This episode features John Mordach, Executive Vice President and Chief Financial Officer, Thomas Jefferson University, Jefferson Health and Jefferson Health Plans. Here, he shares insights into his background & current role, how Jefferson is approaching payer interactions and negotiations right now, areas in 2024 he thinks will be a particular focus from a regulatory perspective, and more.This episode is brought to you by R1 RCM, a leading provider of technology-driven solutions that transform the financial performance of hospitals, health systems, and medical groups. R1 delivers proven, scalable operating models that power sustainable improvements to net patient revenue, while reducing operating costs. To learn how you can build a future-ready revenue cycle today, visit us at www.r1rcm.com/beckers 

Welcome to part one of our three-part series examining the effects of stress on the body. In this episode, interventional cardiologist Dr. David Fischman discusses how stress specifically impacts heart health. Dr. Fischman discusses the differences between acute and chronic stress on the heart and why taking care of your mental health is just as important as taking care of your physical health. Learn about broken heart syndrome and the symptoms of heart disease, plus, his tips on stress management. Resources: Cardiac Widow TikTok Free “How Healthy Is Your Heart” Assessment Listen and subscribe to the Living Well Podcast by Jefferson Health on your preferred players: Spotify, Apple Podcasts, Podbean.

Black and African American people diagnosed with Parkinson's disease (PD) face disparities in healthcare access and outcomes, potentially leading to decreased access to care, resources, and research opportunities. It is crucial to recognize their unique needs and experiences so that scientists can better understand how PD impacts diverse communities. The Parkinson's Foundation aims to identify these healthcare disparities to better serve and support the community. In this first episode of our Black History Month special, Kimberly Gamble, Program Coordinator at Atrium Health, and Lance Wilson, Licensed Social Worker and Center Coordinator at Jefferson Health's Comprehensive Parkinson's Disease and Movement Disorders Center, share real-life examples of outreach strategies that they have used when engaging with the Black and African American community to dispel common misconceptions about research studies, and emphasize the importance of representing and showing up for your community.

Navigating the world of diets and nutrition is no easy task, especially as new diets and trends fight for your attention on social media channels like TikTok and Instagram.   If you've ever wondered if the Keto Diet might be for you, if intermittent fasting could bring you to your weight loss goals, if juicing could help boost your nutritional intake and detox your body, or what exactly “girl dinner” means and how to make one, this episode featuring registered dietitian and licensed dietitian nutritionist Sara Hoffman is for you.   Sara breaks down diets and trends into three categories: trends to leave behind in 2023, those to approach with caution, and those that get a gold-star from Sara. Here are the trends and the minute-mark in which they are discussed:  Trends to leave behind in 2023:  Keto Diet: 2:05  Juicing: 8:25  Metabolism boosters: 12:00  Trends to approach with caution:  Meal replacement shakes/shake-based diets: 15:45  Plant-based diet: 18:25  Protein-packed foods and snacks: 23:05  Hydration boosters/WaterTok: 25:50  Weight loss medications: 28:10  Intermittent fasting: 33:35  Dietitian-approved trends:  “Girl Dinner”: 39:44  Adult Snack Box: 42:43  Mediterranean Diet: 44:35  Listen and subscribe to the Living Well Podcast by Jefferson Health on your preferred players: Spotify, Apple Podcasts, Podbean. 

Socrates tells us the unexamined life is not worth living. We can't improve and move forward without an understanding of where we are. Our guests today, Stephen Klasko, MD, MBA, and healthcare journalist Ken Terry, are on firm ground as they look to the future of healthcare. They have collaborated on a book, Feelin' Alright: How the Message in the Music Can Make Healthcare Healthier. Stephen K. Klasko, MD, MBA, is the former president of Thomas Jefferson University and CEO of Jefferson Health. Ken Terry is a veteran healthcare journalist and author who has written two other books on healthcare reform. Feelin' Alright leverages the emotional power of song lyrics to inspire healthcare executives to envision and build a more accessible, high-quality, and equitable healthcare system. Using music as a metaphor, the author encourages readers to examine what is problematic in the existing healthcare model and to take tangible steps toward a more consumer-centered healthcare experience. Each chapter features Klasko's multifaceted perspective and is anchored with a song that reflects the chapter's central themes. Topics explored include: Why consumers are starting to rebel against traditional healthcare. How technology can be used to transform healthcare through consumer empowerment. How medical education must evolve to prepare physicians for paradigm shifts. What radical changes are needed to decrease health inequity. Learn more about the American Association for Physician Leadership at www.physicianleaders.org

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. In today's episode, we have several news stories to cover. Let's dive right in.## Lawsuits and Mergers:UnitedHealth and its subsidiary OptumRx are facing a lawsuit by Osterhaus Pharmacy in Iowa over the use of "unconscionable" fees imposed by pharmacy benefit managers. The pharmacy alleges that these fees are contributing to the closure of independent pharmacies. Osterhaus Pharmacy is also suing CVS Caremark over similar issues.On the merger front, Jefferson Health and Lehigh Valley Health Network have announced their intent to merge, creating a 30-hospital health system serving Pennsylvania and New Jersey. Wisconsin's Froedtert Health and ThedaCare have also finalized their merger plans, with the combined system set to launch on January 1, 2024.Steward Health Care is facing a lawsuit under the False Claims Act for allegedly improperly billing Medicare for over 1,000 false claims. And approximately 1,800 healthcare workers at Prime Healthcare facilities in Southern California are planning a seven-day strike to protest staffing conditions.The Federal Trade Commission (FTC) and Department of Justice (DOJ) have finalized merger guidelines that could make it more difficult for healthcare mergers and acquisitions to be approved. These new guidelines are expected to give regulators more power to challenge vertical and cross-market deals.## Healthcare Tech and Research:In the healthcare tech space, hospitals are adopting advanced technologies like virtual reality and AI to improve staff burnout and enhance clinical decision-making. Additionally, researchers are exploring how to effectively leverage real-world data to optimize clinical trials and bring new therapies to market. There are also articles on increasing diversity in clinical trials, the development of cell and gene therapies, and the future of oncology research.## Biotech Deals and Intellectual Property:GlaxoSmithKline (GSK) has signed a potential $1.7 billion antibody-drug conjugate (ADC) deal with China's Hansoh Pharma, allowing GSK exclusive rights to develop and commercialize certain ADC products in China. This deal is part of GSK's strategy to expand its presence in China and tap into the growing biopharmaceutical market in the country.Biogen has secured exclusivity for its multiple sclerosis therapy Tecfidera in the European Union until early 2025. This decision upholds exclusive marketing protection for Tecfidera, preventing generic competition until February 3, 2025.These developments highlight the ongoing efforts of pharmaceutical companies to secure partnerships and protect their intellectual property rights. Both GSK and Biogen are strategically positioning themselves in key markets to drive growth and maintain their competitive edge.## Marketing News and Insights:In the marketing world, brands are evolving their influencer strategies and shaping their approaches to popular culture. Pringles and The Caviar Co.'s partnership went viral on TikTok and Instagram, creating a new snacking occasion. Oreo's return to the Super Bowl after a decade is also highlighted, referencing their memorable response to a power outage in 2013.Zacapa Rum is featured in its first global campaign titled "Lips to Soul," focusing on female empowerment. The text mentions sponsored content about building community with Gen Z on social media and rising web traffic on the platform formerly known as Twitter. Oreo will be airing its second-ever in-game spot during Super Bowl LVIII.## Blockbuster Drugs and Predictions:The article discusses the current state of blockbuster drugs in the pharmaceutical industry, noting that COVID-19 vaccines like Pfizer and BioNTech's Comirnaty experienced a rapid rise in sales due to the pandemic. However, it is predicted that sales for COVID-related blockbusters will decline in the coming years.Merck &

What role does nutrition play for patients and caregivers battling ILD? Dr. Gautam George of Jefferson Health joins Crockett to discuss how one can prioritize their nutrition on a daily basis, specific foods that can help, and the role calories play! It's the 'Pulmonary Fibrosis' podcast! Brought to you the Wescoe Foundation for Pulmonary Fibrosis and the Pennsylvania IPF Support Network!Learn more at PAIPFsupportnetwork.org!See omnystudio.com/listener for privacy information.

On this episode of DGTL Voices, Ed welcomes Joseph Cacchione MD, Chief Executive Officer of Thomas Jefferson University and Jefferson Health. Learn more about Thomas Jefferson University, Jefferson Health Plan, and Jefferson Health and the work they are doing to balance the space between health plan and provider to deliver more efficient care.  

If you've experienced any history of cardiac disease or have an established cardiac diagnosis, you're likely already regularly seeing a cardiologist. But what if you haven't? At what point should a cardiologist be a part of your healthcare team?  Cardiologist, Dr. Darius Farzad joins this podcast to answer this question and more. We discuss everything from how your lifestyle could be helping or hurting your heart health, the causes of heart disease, how to manage high cholesterol and the unassuming symptoms you need to be aware of that could be distress signals from your heart.  Listen and subscribe to the Living Well Podcast by Jefferson Health on your preferred players: Spotify, Apple Podcasts, Podbean. 

With Moshe Chasky and Lor Terzian of Alliance Cancer Specialists, Chadi explores the high-stakes lawsuit filed by Alliance against Jefferson Health and Thomas Jefferson University Hospitals, alleging anti-competitive practices that have reverberated throughout the healthcare industry. The duo provides insights into the case, its impact on patient care, and the broader implications for the healthcare landscape. Discover the motivations, legal intricacies, and ethical considerations behind this compelling legal battle that could reshape the future of healthcare in the United States. Read more about the lawsuit. https://www.beckershospitalreview.com/legal-regulatory-issues/oncology-group-sues-jefferson-over-anti-competitive-practices.html Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on Youtube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Infectious diseases expert Dr. John Zurlo returns to the podcast to offer the latest information on COVID-19, including pertinent information on the new boosters and the state of our herd immunity. He also weighs in on who should consider wearing face masks as we see an uptick in COVID cases again this fall.   Listen and subscribe to the Living Well Podcast by Jefferson Health on your preferred players: Spotify, Apple Podcasts, Podbean.

Dr. Alfred Atanda Jr., is a pediatric sports medicine surgeon at Nemours Children's Hospital. He graduated from the University of Pennsylvania School of Medicine and completed his residency training at the University of Chicago. He then went on to complete his fellowship in in pediatric orthopedics at DuPont Hospital (now known as Nemours Childrens) and sports medicine surgery at Jefferson Health. He is also the Director of Clincial Wellbeing at Nemours Children's Health. Dr. Atanda is a motivational speaker touching on topics such as finding one's purpose/calling,  time management, effective communication, daring leadership, continuous improvement, lean thinking, identifying alternative revenue streams, and design thinking. He leverages various digital, social, and multimedia platforms to connect with professionals in a vulnerable way to motivate and inspire them to attain their fullest personal and professional potential. Alfred Atanda: LinkedIn

The Centers for Medicare & Medicaid Services (CMS) is on record saying that Medicare Advantage (MA) payers must follow the Two-Midnight Rule as of Jan. 1, 2024. Yet, it has been reported by multiple hospitals that their MA plans have said their lawyers tell them that they do not have to follow the CMS directions on the Rule relative to inpatient status, claiming their contracts govern their relationships and coverage issues with hospitals.During the next live edition of Monitor Mondays, Dennis Jones, senior director of revenue cycle (a single business office) for Jefferson Health, will report on the arguments that seem to be iginiting a firestorm on the Internet.Broadcast segments will include these instantly recognizable features:• Monday Rounds: Dr. Ronald Hirsch, vice president of R1 RCM, will make his Monday Rounds.• The RAC Report: Healthcare attorney Knicole Emanuel will report the latest news about auditors.• Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Byron, will join the broadcast with his trademark segment.• Legislative Update: Cate Brantley, state legislative analyst for Zelis, will report on the latest legislative actions impacting the healthcare regulatory setting.

This episode features Helene Burns, Senior Vice President & Regional Chief Nursing Officer at Jefferson Health. Here, she discusses key insights into her role & Jefferson Health, the Organization of Nurse Leaders, what recruiting & retaining nurses looks like at Jefferson Health, and more.

Gastroenterologist Dr. David Kastenberg says there's a reason the stomach is referred to as a “second brain.” There are more neurons in the gastrointestinal (GI) tract than there are in the brain. So, if you ever have a “gut feeling” something is wrong, about your health or in your day-to-day life, there's good reason to listen. There's also good reason to listen to this episode, dedicated to GI health. In this episode, Dr. Kastenberg discusses food sensitivities and intolerances, the FODMAP diet, probiotics and prebiotics, common GI disorders and alarming symptoms that you should never ignore. Plus, he offers his perspective on colonoscopy prep and breaks down everything you need to know about colon cancer, including why it's on the rise in younger patient demographics and what symptoms might lead your GI provider to recommend a screening. Listen and subscribe to the Living Well Podcast by Jefferson Health on your preferred players: Spotify, Apple Podcasts, Podbean.

This episode features Alan Condon, Editor-in-Chief at Becker's Healthcare. Here, he discusses CHS planning to sell 3 hospitals to Tampa General and Jefferson Health reducing its workforce by approximately 1% or about 400 positions.

In this episode, primary care physicians Drs. Tito Mantilla and Arun Thomas share the top questions their patients are bringing to their appointments. They offer their thoughts on weight loss medications, the importance of preventative screenings, managing chronic disease, when is the right time to start anxiety medications and more.   Listen and subscribe to the Living Well Podcast by Jefferson Health on your preferred players: Spotify, Apple Podcasts, Podbean. 

Drs. Allison Zibelli and Arielle Heeke discuss the NATALEE trial's novel approach to high-risk HR+ breast cancer, the potential of delaying CDK4/6 inhibitors in HR+, HER2-negative mBC to decrease toxicities and costs in the SONIA trial, and de-escalation strategies in HER2+ early-stage breast cancer. TRANSCRIPT Dr. Allison Zibelli: Hello. I'm Dr. Allison Zibelli, your guest host for the ASCO Daily News Podcast today. I'm an associate professor of medicine and a breast medical oncologist at the Sidney Kimmel Cancer Center at Jefferson Health in Philadelphia. My guest today is Dr. Arielle Heeke, a breast medical oncologist at the Levine Cancer Institute at Atrium Health in North Carolina.  Today, we'll be discussing practice-changing studies and other key advances in breast cancer that were featured at the 2023 ASCO Annual Meeting.   Our full disclosures are available in the show notes and disclosures of all guests on the podcast can be found on our transcripts at asco.org/DNpod.   Arielle, it's great to speak with you today.   Dr. Arielle Heeke: Thank you so much for having me.  Dr. Allison Zibelli: Let's start with LBA500. This was the NATALEE trial of ribociclib and endocrine therapy as adjuvant treatment in patients with hormone receptor-positive HER2-negative early breast cancer. What are your key takeaways from the study, and how do you think this changes our approach to high-risk ER-positive breast cancer?  Dr. Arielle Heeke: Yeah, this was definitely the study for which many of us were waiting to see the results. It was exciting to see the results come through so quickly. As you mentioned, the NATALEE trial was a phase 3 study that evaluated three years of adjuvant ribociclib at a dose of 400 milligrams, which is a little different than what we're used to in the metastatic space at 600 milligrams. But essentially, it randomized patients to receive this 400-milligram dose with their adjuvant aromatase inhibitor therapy versus just the standard of care adjuvant endocrine therapy in patients that are high risk with early-stage breast cancer.   What made NATALEE somewhat unique is they defined high risk a little bit more broadly than we've seen in previous studies, such as monarchE. So, what I mean by that is NATALEE enrolled patients with stage 2 and 3 early-stage breast cancer. And notably, they allowed for patients that were lymph node-negative but had some other high-risk features, such as a grade 3 tumor or a grade 2 tumor with high-risk genomics, such as oncotype or a high Ki-67. So, by broadening who was eligible, NATALEE captured more patients at risk for recurrence. Of course, we know that recurrence is not specific for patients with lymph node-positive disease. We can see recurrence even with stage 1, but certainly, we start to see more recurrence risk as patients drift into stage 2 and stage 3.   In the NATALEE study, the majority of these patients did receive prior chemotherapy, which I also think is interesting. We've kind of seen in the metastatic space that sometimes chemotherapy can augment patients' responsiveness to CDK4/6 inhibitors. But specifically in NATALEE, 88% of patients had received prior chemotherapy, and ultimately, about a third of the patients were lymph node-negative.   So, diving into some of the results with this first analysis that we saw at ASCO, with the median follow-up for invasive disease-free survival of just 27.7 months, they were able to show that the risk for invasive disease was reduced by 25.2% with the addition of ribociclib plus endocrine therapy compared to endocrine therapy alone. And this three-year invasive disease-free survival rate was 90.4% for the combination therapy compared to 87.1% for endocrine therapy alone, which is an absolute difference of 3.3%. Additionally, patients treated with ribociclib and endocrine therapy had a 26.1% reduced risk for distant disease-free survival compared with endocrine therapy alone, and this was a rate of 90.8% for ribociclib with endocrine therapy compared to 88.6% with endocrine therapy alone, which correlates to an absolute benefit of 2.2%.    They did show results for overall survival as well, but again, follow-up was just a median of 27.7 months. So, data was essentially immature to show any true overall survival benefit from this approach. And in fact, only 20% of patients had completed three years of ribociclib at this data cutoff. And as a reminder, again, NATALEE involved ribociclib for three years compared to two years, which we've seen with other studies in this space.   Also, what was encouraging from NATALEE were the readouts for toxicities. Neutropenia is definitely a concern with this class of medication, and they were able to show that rates of neutropenia were overall lower than what we've seen in the pooled data in the metastatic space. And also that problematic QTc prolongation for which we have to get EKGs baseline two weeks and four weeks. They also showed that the likelihood of having QTc prolongation on this therapy was significantly less at that 400-milligram dose compared to 600.   I think the key takeaway is yes, this drug is effective as adjuvant therapy, which is perhaps not surprising since we've seen such promising results in the metastatic space, but numerically not as striking as what we have at this point with adjuvant abemaciclib, but of course, this is a newer study. We hope to see that continued separation of the curves as we were fortunate enough to see with the abemaciclib data, but obviously we'll be looking for additional analyses from NATALEE.    And then how this will change practice, of course, we'll have to wait to see if the therapy is approved for use in the adjuvant setting for early-stage hormone receptor-positive breast cancer, but it certainly will be a nice option for patients that struggle with GI toxicity kind of at baseline. But also, if they were previously on abemaciclib and were not able to tolerate due to the GI toxicity, this would be an option for them. Also, as mentioned, it's a broader patient population, so we can consider this perhaps for a patient with lymph node-negative disease.   Although we will have to ask ourselves that just because someone meets eligibility for the NATALEE  study, and if the therapy is ultimately approved, is it appropriate to give it to all those patients? Or do we need to still kind of think of this in the setting of the highest-risk patient, not just any patient with stage 2 plus disease? There was a lot of talk at the meeting, certainly about biomarkers and potentially using ctDNA to try to find these predictors of benefit from CDK4/6 inhibitor therapy, but obviously, still a long way to go before we can use that type of technology in this space.  Dr. Allison Zibelli: Thank you. Staying on the topic of CDK4/6 inhibitors, everybody was excited about the SONIA trial, which was LBA1000, and this trial was asking if we can delay using CDK4/6 inhibitors for newly diagnosed ER-positive HER2-negative metastatic breast cancer as a way to decrease both toxicity and cost. Tell us about this study.  Dr. Arielle Heeke: The SONIA trial was such a cool study to see, and the presenter reported findings in such a thought-provoking way. Really great to see this sort of work being done because I think we all wonder deep down in our gut, if more is more, or if we do need to kind of be a little bit more thoughtful about how we introduce these therapies certainly from a patient perspective. Patients that participate at ASCO [meetings] have been saying for years how important it is to consider the toxicities in terms of side effects, but also, of course, financial toxicities. So, it was great to see the SONIA trial at center stage.   Essentially, as you mentioned, it was a study that randomized patients in the first-line setting with metastatic hormone receptor-positive breast cancer to receive either first-line CDK4/6 inhibitor therapy or second-line CDK4/6 inhibitor therapy. So basically, there was a mandated crossover, so patients that received the CDK4/6 inhibitor first-line did not receive a second line and vice versa. Patients that were randomized to receive their endocrine therapy as monotherapy first line went on to receive CDK4/6 inhibitor at second-line. And the second-line endocrine therapy was fulvestrant in both of those situations.    We kind of run into this problem with patients now where we have so many therapies available to us that we don't typically run out of treatment options, but rather we run up against treatment toxicity or ultimate failure of the human body to keep up with the demands of ongoing therapy. So, again, while it's maybe somewhat attractive to start treatments earlier using things first-line rather than second-line or longer, just kind of post-CDK4/6 inhibitor progression, you know using this CDK4/6 inhibitor again with a different endocrine therapy backbone is probably not offering a meaningful benefit to that many patients. So this type of study is so necessary to really try to help us frame who needs those therapies sooner and longer or perhaps is there a substantial portion of patients that we don't need to put them through that sort of toxicity.   So that's the SONIA trial. Some things to note about the patient population, these patients were a bit older than what we've seen in some of our metastatic CDK4/6 inhibitor trials. There was a median age of 64 and 87% were postmenopausal. Additionally, just 40% had received prior chemotherapy. And as is true for most of our studies, 91% have received palbociclib on study with just 8% receiving ribociclib. And the choice of the CDK4/6 inhibitor was per the treating provider, and at the time of the of study globally, palbociclib was the more commonly prescribed CDK4/6 inhibitor. But over the last year or so, data has certainly emerged favoring ribociclib in the metastatic setting.   On the SONIA trial, patients were monitored for a median of 37.3 months. And looking at the primary endpoint of the second progression-free survival, which is defined as the time for random assignment to the second objective disease progression or death, for those patients who received first-line CDK4/6 inhibition, had a PFS2 of 31 months compared to 26.8 months with second-line CDK4/6 inhibitor use. And this slight difference was non-statistically significant. So the conclusion was that time to second progression was not impacted by whether or not a patient received first-line CDK4/6  inhibition or second-line CDK4/6 inhibition. Additionally, there were no differences in overall survival between the 2 arms with a median overall survival of 45.9 months with first-line CDK4/6 inhibitor use versus 53.7 months in second-line CDK4/6 inhibitor use.  And that actually equates to significant differences in time on drug. The median duration of CDK4/6 inhibitor use with first-line therapy was 24.6 months compared to 8.1 months with second-line use. And by being on therapy for an additional 16.5 months if you use CDK4/6 inhibitor first-line, this, of course, leads to increased toxicity and certainly increased financial burden. And it was estimated that for each patient that receives this therapy first-line, there is an additional $200,000 spent on getting them the CDK4/6 inhibitor first-line, whereas the results from SONIA suggested that whether you use it first-line or second-line, the outcomes are essentially exactly the same.   And then specific for the SONIA trial, by conducting the study, they saved approximately €25 million on drug expenditure during the conduct of the trial. It's just amazing when you take it to that scale. And then lastly just to mention, they looked at quality of life assessments as well and there were no differences in the two arms whether they got first-line or second-line CDK4/6 inhibition.  Dr. Allison Zibelli: I thought this study was remarkable, and it got a long ovation when it was presented at the meeting. I'm certainly going to use this strategy and prioritize who needs upfront CDK4/6 inhibitor therapy.  I think that we have to think of not just drug toxicity for our patients, but financial toxicity. A lot of these drugs have very high copays and the number one cause of bankruptcy in the United States is medical costs. So that's something we really have to keep in mind. I also thought it was very interesting that the study was designed in cooperation with the patient advocacy group and patients themselves were very enthusiastic about this study and helped design it and helped recruit to it. So all in all, I thought this was a remarkable study.    So moving on, LBA1013 was the TORCHLIGHT study of toripalimab versus placebo in combination with nab-paclitaxel for patients with metastatic or recurrent triple-negative breast cancer. Many of us are not familiar with toripalimab. Can you tell us about the drug and how it was used in this study?  Dr. Arielle Heeke: Yes, toripalimab is essentially an immunotherapy agent. It's an IgG4K monoclonal antibody that targets PD-1. In this study, TORCHLIGHT, patients were randomized to receive toripalimab versus placebo in combination with nab-paclitaxel in newly metastatic triple-negative breast cancer. The patients on study were randomized two to one to receive drug or placebo. The drug is given on day 1 of a 3-week cycle at 240 milligrams and then patients of course also receive nab-paclitaxel on a day 1 and day 8 schedule of a 21-day cycle. They did look at outcomes on the study based on PD-L1 positivity status and they assessed for PD-L1 with an IHC assay JS311 antibody that ultimately generated a combined positive score. And PD-L1 positivity was defined as a CPS of greater than or equal to one based off of this assay. In the study population, about a third of patients were- patients' tumors were CPS negative, a third had a CPS of 1 to 10 and about a quarter had a CPS of greater than or equal to 10. And then approximately 7% of the tumors had an unknown status.   And then getting right into the results, we were provided results in the PD-L1 positive subgroup as well as the whole patient population. Looking at the primary endpoint of PFS, there were significant improvements seen in median PFS with the addition of toripalimab to nab-paclitaxel, again in the first line setting with a median PFS of 8.4 months with the addition of the immunotherapy agent versus 5.6 months with placebo. And this was statistically significant.  And then in the intent to treat population, there were some numeric improvements, in median, progression-free survival at 8.4 months with the addition of toripalimab versus 6.9 months with placebo.   We also got some results with overall survival that were quite intriguing, although this initial analysis was not designed to necessarily prove statistically significant differences in overall survival. But again, there were some promising trends. Looking first at the PD-L1 positive subgroup, the median overall survival was 32.8 months with the addition of toripalimab versus 19.5 months with placebo. Breaking it down a little bit further based on CPS values, for a CPS of 1 to 10, median overall survival was 32.8 months versus 19.5 months. And then for those very high CPS or greater than or equal to ten, median overall survival was not reached in this group versus 18.3 months with placebo. Also, looking in the intent-to-treat population, there were also improvements in overall survival with the addition of toripalimab with a median overall survival of 33.1 months with the addition of immunotherapy versus 23.5 months with nab-paclitaxel alone. So potentially, depending on next steps of this study, we would potentially have an option to add immunotherapy that is not biomarker specific, meaning we can potentially provide toripalimab to all patients regardless of their PD-L1 status.  Dr. Allison Zibelli: Very interesting new drug to look forward to. So, one of the major themes of this year's meeting was de-escalation strategies. For example, LBA506 reported the three-year invasive disease-free survival of the PHERGain trial, which looked at eliminating chemotherapy for HER2-positive patients getting neoadjuvant therapy. Tell us about the design of this study and how will it impact the care of these patients?   Dr. Arielle Heeke: The design was very complicated. I had to look at it a few times to really make sure I got my head around it. But I think once you do figure it out, you can see how there might be a path forward in clinical practice. Although I think for all of this work, it's maybe not ready yet for primetime, but certainly thought-provoking. But the PHERGain clinical trial, I feel like we've heard about this study for a little while and this concept of de-escalation really kind of started in the HER2-positive space. But this study was a randomized study of chemotherapy de-escalation and early HER2-positive breast cancer using PET/CT as a marker of response to therapies that don't involve chemotherapy.   Patients were eligible for the study if they had stage 1 to 3a HER2-positive breast cancer with no prior therapy for breast cancer, and ultimately 356 patients were enrolled in a 1 to 4 randomization scheme with the majority of patients ultimately enrolled into the experimental group, which is called Group B. So, to break down Group A and Group B, Group A essentially were patients that receive typical standard of care, which at this point is TCHP for six cycles, neoadjuvantly or prior to surgery. Once they complete those cycles they move into surgery and then Herceptin-PERJETA adjuvantly for additional twelve cycles.  I should also note that this study was conducted prior to results of the KATHERINE trial that showed benefit of switching to adjuvant T-DM1 if there's residual disease. So, patients in Group A as well as Group B did not receive T-DM1 at any point. So, again, Group A is kind of your standard of care. Group B was the “experimental arm.” And so, what they did in this arm to assess potential de-escalation strategies, patients first received Herceptin-PERJETA alone for two cycles with or without endocrine therapy, if they were also hormone receptor-positive. But after those two cycles, they underwent a PET/CT, and then if a response was garnered, they would continue with Herceptin-PERJETA and again plus or minus endocrine therapy to complete six cycles total before proceeding on with surgery. Then if they were fortunate enough to achieve complete response at the time of surgery, then they just continued with Herceptin-PERJETA maintenance, whereas if they did not achieve a complete response at the time of surgery, then they actually received TCHP 6 times adjuvantly. So, the chemotherapy was introduced after surgery.   And then going back to that PET/CT time point, if patients did not achieve a response at that check-in point, after 2 cycles of Herceptin-PERJETA, at that point they were transitioned to chemotherapy with TCHP, again, for six cycles. So, either they could kind of ride all the way through if they got that complete response at the time of surgery with Herceptin-PERJETA only, or if at surgery there was residual disease, they went on to receive TCHP after surgery, or if they did not have a response on that interim PET/CT after 2 cycles of HP then they would go on to receive TCHP neoadjuvantly.    So, looking at the results, they actually had 2 primary endpoints. The first primary endpoint was rates of a complete response at the time of surgery in patients that had a PET response. So, PET responses were actually seen in nearly 80% of all the patients treated with Herceptin-PERJETA without chemotherapy. And in those PET responders, a complete response rate at the time of surgery was seen in approximately 38% of patients. So, 37.9% of PET responders actually achieved a complete response when they went to surgery after receiving Herceptin-PERJETA alone, which is pretty amazing. I mean, we're used to seeing higher complete response rates with neoadjuvant therapy for HER2-positive disease, but again, this is a chemo-free regimen so that is encouraging for that 38% of patients that really didn't need chemotherapy.   And then the second primary endpoint, and this was what we saw basically for the first time with the 2023 ASCO Meeting, was results for the 3-year invasive disease-free survival in Group B or this experimental de-escalation group. And ultimately it was shown that the three-year invasive disease-free survival and the intent to treat group B population was 95.4%, which met its statistical endpoint, or, basically the null hypothesis was rejected. They just needed some sort of outcome that was not worse in terms of the 3-year invasive disease-free survival of 89%.   And then looking actually at the patients that kind of did the best. So, the patients that were PET responders and achieved a complete response at the time of surgery and therefore really only ever received Herceptin-PERJETA, their three-year invasive disease-free survival was 98.8%. So, really very good. Additional endpoints they looked at in Group A and Group B were favorable in terms of three-year invasive disease-free survival in Group A, and then three-year distant disease-free survival and three-year overall survival in both groups, all approximately 98%. So, very favorable.   So, ultimately, these findings reflect a potential role for a chemotherapy-free treatment approach for some patients with early-stage HER2-positive breast cancer. And this particular study, they used PET/CT to influence chemotherapy decision-making, which potentially identified 1 in 3 patients who can omit chemotherapy. With that, 80% of patients receiving the response with a PET/CT, and then of that, 80%, again, 38% actually having that complete response. And ongoing work is also being done to look at other mechanisms to assess for an opportunity to de-escalate with MRI imaging or HER2DX testing to again try to identify patients who can potentially defer chemotherapy in this setting. I did not see from the results what proportion of patients were hormone receptor-positive, which I think is also interesting when thinking about chemotherapy de-escalation, can you lean a little bit more heavily on endocrine therapy? Perhaps we'll get that data in the future.   Dr. Allison Zibelli: That's a very important point.  I would like to thank you, Dr. Heeke, for coming on the podcast today and sharing your valuable insights with us. We really appreciate it.  Dr. Arielle Heeke: Absolutely. It was a great meeting to dive into. It's always exciting to see what comes out of ASCO in the breast space. We're usually well represented there, and I hope that these studies will lead to further exploration.   Dr. Allison Zibelli: And thank you to our listeners for joining us today. You'll find links to all abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.  Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  Follow today's speakers:   Dr. Allison Zibelli   Dr. Arielle Heeke  @HeekeMD     Follow ASCO on social media:    @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn      Disclosures:    Dr. Allison Zibelli:    None Disclosed   Dr. Arielle Heeke:   Honoraria: Merck  Consulting or Advisory Role: Jazz Pharmaceuticals, Caris Life Sciences, Amgen, Daiichi Sankyo/Astra Zeneca, Pfizer, AstraZeneca, Menarini, Genome Insight  Speakers' Bureau: Daiichi Sankyo/Astra Zeneca      

Charles J. Yeo is a hepatopancreaticobiliary surgeon here at Jefferson. He was born in East Orange, New Jersey, and attended Spring Valley Senior High School in Spring Valley, New York. He received his undergraduate degree from Princeton University in 1975, summa cum laude with an A.B. in Biochemistry. Dr. Yeo graduated in 1979 from the Johns Hopkins University School of Medicine, being awarded the Upjohn Achievement Award and he was elected to Alpha Omega Alpha and Phi Beta Kappa. While completing his internship and residency in General Surgery at the Johns Hopkins Hospital, he pursued a one year Research Fellowship at the S.U.N.Y. Downstate Medical Center in Brooklyn, N.Y. Dr. Yeo joined the faculty of the Johns Hopkins University as an Instructor and Assistant Chief of Service in the Department of Surgery in 1985, and rose to the rank of Professor of Surgery in 1996. In 1997, he became a Professor in the Department of Oncology. Dr. Yeo directed the Pancreatic Cancer Interdisciplinary Working Group at Johns Hopkins, and served as the Surgical Clerkship Coordinator and Surgical Curriculum Consultant. In 2002, Dr. Yeo was named to an endowed chair at Johns Hopkins, becoming the inaugural John L. Cameron M.D. Professor for Alimentary Tract Diseases. On October 1, 2005 Dr. Yeo was named the 8th Samuel D. Gross Professor and he assumed the chairmanship of the Department of Surgery at Jefferson (now Sidney Kimmel) Medical College of Thomas Jefferson University in Philadelphia, Pennsylvania. He currently serves on the Board of Trustees of the Thomas Jefferson University Hospitals, and as the Senior Vice President and Chair of Enterprise Surgery for Jefferson Health (an 18 hospital system). Dr. Yeo has authored over 500 peer reviewed scientific papers, 105 book chapters, and over 15 books or monographs. Dr. Yeo is also known as the “Whipple King” having completed over 1700 Whipple procedures and treated 2100 patients with pancreatic and related cancers. Thank you so much Dr. Yeo for taking the time to speak with me.All proceeds from this episode go to Friends Against Pancreatic Cancer Fund and the Drs. Francis and Ernest Rosato Fund for Surgical Education and Research.___0:00 - Intro2:22 - What Is Hepato Pancreato Biliary Surgery?3:00 - Whipple Procedure9:13 - Treating Pancreatic Cancer14:15 - How Did You Become the Whipple King?17:14 - Navigating and Choosing Surgery in Med School25:57 - Residency32:41 - Memorable Experiences While at John Hopkins37:11 - Going Into Hepato Pancreato Biliary Surgery51:44 - An Average Day/Week as a Chair of Surgery56:40 - Best Thing About Being an HPB Surgeon58:52 - Worst Thing About Being an HPB Surgeon1:05:16 - Differences in Becoming the Chair of Surgery1:08:16 - Best Things About Working in Academia 1:10:28 - Characteristics of the Best Med Students/Residents1:11:26 - Maximizing Competitiveness Going Into Surgery1:14:10 - Favorite Historical Surgeon1:15:42 - Responsibility of Surgeons in Advocacy of Social Change1:17:30 - Advice for Graduating Med Students1:19:58 - Very Important Question!!!1:22:31 - Closing Message1:23:52 - Outro___ResourcesThe Smart Take from the Strong by Pete Carril - https://a.co/d/is7c0cN___View the Show Notes Page for This Episode for transcript and more information: zhighley.com/podcast___Connect With ZachMain YouTube: @ZachHighley Newsletter: https://zhighley.com/newsletter/Instagram: https://www.instagram.com/zachhighley/?hl=enWebsite: https://zhighley.comTwitter: https://twitter.com/zachhighleyLinkedln: https://www.linkedin.com/in/zach-highley-gergel-44763766/Business Inquiries: zachhighley@nebula.tv___Listen for FreeSpotify: https://open.spotify.com/show/23TvJdEBAJuW5WY1QHEc6A?si=cf65ae0abbaf46a4Apple Podcast: https://podcasts.apple.com/us/podcast/the-zach-highley-show/id1666374777___Welcome to the Zach Highley Show, where we discuss personal growth and medicine to figure out how to improve our lives. My name is Zach and I'm a medical student, and soon to be physician, in Philadelphia. Throughout these episodes I'll interview top performers from around the world in business, life, and medicine in hopes of extracting the resources and techniques they use to get to the top.The best way to help the show is share episodes on any platform. If you think a friend or family member will like a certain episode, send it to them!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Stephen Klasko is a transformative leader and advocate for a revolution in our systems of health care and higher education. He has been a university president, a dean, a CEO, and an obstetrician, and now pursues his vision for the creative reconstruction of American healthcare by bridging traditional academic centers with entrepreneurs and innovators. His passion is using technology to eliminate health disparities and offers everyone the promise of health assurance. Dr. Klasko is also a lifelong DJ who believes that the message in the music can give us the courage to tackle a broken, fragmented, unfriendly, expensive, and inequitable healthcare system. In this episode, Dr. Klasko merges with his alter ego “Stevie K the DJ” to discuss his new book, “Feeling Alright: How the Message in the Music can Save Healthcare” published by ACHE.  Feelin' Alright leverages the emotional power of song lyrics to inspire healthcare executives to envision and build a more accessible, high-quality, and equitable healthcare system. Using music as a metaphor,  Dr. Klasko encourages us to examine what is problematic in the existing healthcare model and to take tangible steps toward a more consumer-centered healthcare experience. Infused with the passion inherent in music, this interview motivate healthcare leaders to take the lead in building a better healthcare system! Episode Bookmarks: 01:20     DJ Eric “The Dream” Weaver introduces Dr. Stephen Klasko (aka Stevie K the DJ)! 03:30 Support Race to  Value by subscribing to our weekly newsletter and leaving a review/rating on Apple Podcasts. 04:30 Using the power of music to inspire a more optimistic world. 05:30 Dr. Klasko discusses his prior career as a DJ and how getting fired started him on the path to medicine. 06:30 Using music at Jefferson to inspire his others to find hope in overcoming the pandemic, financial tsunami, and systemic racism. 07:00 “Choice of Colors” by Curtis Mayfield and the Impressions (healing during the George Floyd protests) https://www.youtube.com/watch?v=Zr0SLv9WFr4 07:45 “Courage to Change” by Sia become a theme song for frontline workers and their heroic response to the COVID-19 pandemic. https://www.youtube.com/watch?v=mWQACEqf4QY 10:00 Health care delivery during the pandemic was a war and how music helped to see a brighter day. 10:45 “We have to stop saying we are the best healthcare system in the world.” 11:00 “Medicine's Dilemmas: Infinite Needs Versus Finite Resources” and the “Iron Triangle” of Healthcare 11:30 The performance of stocks as evidence for flawed thinking around healthcare disruption. 12:30 Kaiser Permanente and Geisinger come together to launch Risant Health and expand access to value-based care. 13:00     Payer-Provider Alignment in Medicare Advantage 13:45 Cityblock Health leveraging capital investment to build a Community Health Worker model for population health. 14:30     Taking population health, social determinants, predictive analytics, and health equity to the mainstream of healthcare. 14:45 “Keep the Customer Satisfied” by Simon & Garfunkel as inspiration for health assurance to rebuild trust and equity in a broken system. https://www.youtube.com/watch?v=qx6_0Do0qGQ 17:00 In healthcare, do we really view the people as the customer? 18:00 The healthcare system is setup to enrich the people in control. 18:30 “The concept behind health assurance is that costly sick care will give away to affordable, personalized, and preemptive care, partly through genomic sensors and AI-based digital therapies.” 19:00 The future of Jefferson as a health system without a location. 20:00 Livongo and Jefferson Health -- a strong, sustainable partnership between technology and providers to remake medicine. 21:00 Poor consumer segmentation in American healthcare (viewing patients monolithically). 22:45 Radical change needed! (collaboration,

We discussed a few things including:  1. Klasko's healthcare and innovation journey2. His tenure at Jefferson3. Industry challenges and opportunities4. Insights/trends relating to health and education sectors5. His new book and how music and DJing have affected his lifeStephen Klasko, M.D., M.B.A. is an author, an entrepreneur and a believer in the creative and optimistic transformation of healthcare and higher education. He has been a CEO, a university president, and a dean of two medical colleges. Currently he is pursuing his passion to bridge academic health centers with the emerging world of #digital medicine and #innovation.  As President of Thomas Jefferson University, he directed a merger between an almost two century old health science university and a nationally ranked university for design and architecture, heralded by the Chronicle of Higher Education as one of the “few successful mergers between academic entities.”  As CEO of Jefferson Health, he presided over the growth of the system from $1.5 billion to $9 billion including the acquisition of Health Partners Plan, making Jefferson the first integrated delivery and financial system in Philadelphia history.His most recent book, “Feelin' Alright: How the Message in the Music Can Make Healthcare Healthier” uses music and creativity to tackle some of the thorniest issues in healthcare, academics and health equity. His fifth book (with Hemant Taneja of General Catalyst) in 2021, “UnHealthcare: A Manifesto for Health Assurance” has become the manual for both founders and health system CEOs for bringing together the venture capital world with the traditional healthcare ecosystem and has been translated in several languages.Dr. Klasko serves as an Executive in Residence at General Catalyst, North American ambassador for Sheba Medical Center in Israel, and as CMO and Operating Partner of Abundant Venture Partners.  He is also the lead independent director of Teleflex, a seventy-year-old NYSE medical device company. In 2022, President Biden appointed him to the National Board of Education Sciences.Over the past five years he has been awarded by Fast Company as one of the “top 25 most #creative people in business,” by Modern Healthcare as the “#2 most influential person in #healthcare” and by Ernst and Young as the “#entrepreneur of the year.”#healthtech#podcast #AFewThings